Skip to main
AXSM
AXSM logo

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 47%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. reported third-quarter revenues of $136.1 million, exceeding consensus estimates and demonstrating a robust year-over-year growth of 69% alongside a quarterly increase of 14%, supported by approximately 209,000 prescriptions. The company's improved payer coverage, now at 85%, enhances its market accessibility, contributing to revenue potential as they also plan to launch a pediatric ADHD study and anticipate key data releases for other indications in 2026. Furthermore, Axsome's ongoing product innovations and anticipated operational leverage indicate a trajectory toward achieving positive cash flow by 2026, enhancing its investment appeal.

Bears say

Axsome Therapeutics Inc. is projected to experience modestly declining revenues, with the full-year 2025 forecast set at $628.3 million compared to $630.5 million previously. The company faces significant risks, including potential setbacks in clinical trials for key products like AXS-05 and AXS-12, as well as uncertainties regarding market access for AUVELITY and competition impacting commercial success. Additionally, regulatory approval delays and long-term dilution risks further exacerbate concerns about its financial stability and growth prospects in the highly competitive CNS therapeutics market.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 47% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.